title: Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2.
abstract: Major surgery suppresses host immune reactivity through alterations in monocyte and T cell-derived cytokine, eicosanoid and acute-phase protein release. Recombinant interleukin (IL) 2 augments T lymphocyte and monocyte activity in vitro. Eighteen patients, with localized colorectal cancer, were randomized to receive either recombinant IL-2 or placebo for 3 days by subcutaneous injection before surgery. Serum levels of IL-1 beta, IL-6, tumour necrosis factor alpha, soluble IL-2 receptor, C-reactive protein (CRP) and albumin were measured, and T lymphocyte surface expression of HLA-DR and CD25 and neutrophil phagocytosis were determined, before and for 21 days after surgery. Significant augmentation of IL-6, CRP and soluble IL-2 receptor production, enhanced expression of activation markers and increased neutrophil activity were found. Recombinant IL-2 may have a role in ameliorating the immunosuppression found after major surgery.
authors.affiliation: Department of Surgery, University of Aberdeen, Foresterhill, UK.
authors.forename: D J
authors.initials: DJ
authors.lastname: Deehan
authors.forename: S D
authors.initials: SD
authors.lastname: Heys
authors.forename: W
authors.initials: W
authors.lastname: Simpson
authors.forename: J
authors.initials: J
authors.lastname: Broom
authors.forename: D N
authors.initials: DN
authors.lastname: McMillan
authors.forename: O
authors.initials: O
authors.lastname: Eremin
mesh_terms: D000210:Acute-Phase Reaction / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000032:analysis; D015179:Colorectal Neoplasms / Q000097:blood / Q000276:immunology / Q000601:surgery* / Q000628:therapy; D016207:Cytokines / Q000097:blood*; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007375:Interleukin-1 / Q000097:blood; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis; D011300:Preoperative Care; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D012709:Serum Albumin / Q000032:analysis; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D016207:Cytokines; D006684:HLA-DR Antigens; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D012709:Serum Albumin; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein